The Essential Biodata Life Science Partner in Rare and Neurodegenerative Diseases

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.

>800,000

Individuals in the CENTOGENE Biodatabank

>400,000

Collected biosamples

30,000

Active physicians in our network

>19,000

Genes covered in testing portfolio

Working together with our patients, physicians, and partners to diagnose, understand, and treat rare, metabolic, and neurodegenerative diseases.

About our company

CentoCloud News

The FilterTool is available now!

CENTOGENE’s FilterTool is one of the world’s only CE-marked In Vitro Diagnostic Regulation (IVDR 2017/746) filtering applications to support experts in genomic diagnostics.

Discover more

Diagnose.

CENTOGENE Baby Hand image reference nathan-dumlao-EytWx3BOrwI-unsplash

Diagnose.

To create a map, we integrate omic data from patients with the same disease to form an atlas representing a comprehensive collection of unique and detailed clinical and biochemical information about each rare disease.

Learn more

Understand.

CENTOGENE Why Choose Header Helix DNA

Understand.

Understanding the details of disease pathways – faulty genes and how they affect associated proteins, and how that leads to specific symptoms – can provide our pharmaceutical partners with valuable clues on how best to research treatments, by developing a drug to target specific molecules along disease pathways for example.

Learn more

Treat.

CENTOGENE Operationalising Clinical Trials Laboratory Scene

Treat.

The combination of omic technologies can identify drugs and drug targets with greater certainty, reducing the risk of failure and making drug development for rare diseases more financially attractive to pharma. Our goal: to enable the cure of 100 diseases in 10 years.

Learn more

Top Company News

CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, September 11, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science…

Read more

CENTOGENE Reports First Half 2023 Financial Results

Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance

Read more

CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients

CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases,…

Read more

Visit Our Online Ordering Portal

CentoPortal® is a user-friendly, online, web-based ordering portal designed to assist you at every step of processing your patients' samples.

Go to CentoPortal

CENTOGENE CentoPortal Logo